For over 50 years, Guthrie has been conducting oncology clinical trials and we are proud to have been affiliated with multiple institutions, including University of Rochester, Cornell University and Vanderbilt. Our current collaborator for National Cancer Institute (NCI) trials is the Mayo Clinic in Rochester, Minnesota. This collaboration allows access to trials through the NCI’s National Clinical Trials Network (NCTN), a research network that provides treatment, screening, and diagnostic trials to over 3,000 clinical sites across the nation. Through this partnership, we’re able to begin clinical trials quickly, reach conclusions faster and offer studies that incorporate precision medicine and novel therapies that otherwise may not be available.  

Leading-edge research delivered locally - As a Guthrie patient you may have the unique opportunity to take part in one or more of nearly 100 clinical research trials that involve new investigational treatments for many cancer types, and the potential to participate in select trials of novel cancer drugs. If you’re at risk for certain types of cancer, screening and prevention trials are also available. Guthrie research scientists are investigating several projects designed to explore cancer trends in our region and how they may affect the next generation of residents.

Clinical Trials

Clinical trials study new ways to prevent, detect and treat cancer. The NCI approves, oversees and provides funding for a large percentage of oncology clinical trials conducted each year in the United States. Guthrie’s participation in this network provides you access to valuable clinical trials without the burden and expense of traveling to a major metropolitan area.

As a result, you receive excellent care locally from the Guthrie Cancer Center team, while still being able to access cutting edge investigational therapies that are offered in large university settings and metropolitan areas. Clinical cancer trials might involve preventive measures and/or treatments, including chemotherapy, biotherapy, supportive care medications, radiation, experimental surgical techniques or devices, lab draws and/or alternative medicines. 

Your physician can present you with options and help you determine whether a clinical trial is right for you. Most clinical trials offered at Guthrie are phase 2 or phase 3 studies which measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, biotech companies, and the NCTN to offer you the chance to get innovative treatments, novel therapies and to assist with the future of cancer care. 

Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT06096844
Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Gilead Sciences
Details (Identifier #): NCT05633654
Title: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of
Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus
Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06236438
Title: A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Kasireddy MD, Vineela

Sponsors: ALLIANCE
Details (Identifier #): NCT04457596
Title: A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Details (Identifier #): NCT04340141
Title: A151216 ALCHEMIST, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator:

Lash MD, Bradley

Sponsors: ALLIANCE
Details (Identifier #): NCT02194738
Title: ALLIANCE A222004:
A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Department: Oncology
Diagnosis: Not applicable
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT04964934
Showing 1-10 of 28 Results